Anti-IgM Monoclonal Antibody (Clone:CH2)

Anti-IgM Monoclonal Antibody (Clone:CH2)
Artikelnummer Größe Datenblatt Manual SDB Lieferzeit Menge Preis
ABE-30-1204-0.1 100 µg -

3 - 11 Werktage*

536,00 €
 
Immunoglobulin M (IgM) is produced as a 900 kDa pentamer, which is an efficient complement... mehr
Produktinformationen "Anti-IgM Monoclonal Antibody (Clone:CH2)"
Immunoglobulin M (IgM) is produced as a 900 kDa pentamer, which is an efficient complement binder. This antibody type is produced initially in the immune response and it is the first immunoglobulin class to be synthesized by a fetus or newborn. IgM antibodies do not cross the placenta. IgM concentration in blood is 0.12 g/l and its biological survival (plasma T1/2) is 5 days. Protein function: Secreted protein that acts as a key regulator of lipid synthesis: mainly expressed by macrophages in lymphoid and inflammed tissues and regulates mechanisms in inflammatory responses, such as infection or atherosclerosis. Able to inhibit lipid droplet size in adipocytes. Following incorporation into mature adipocytes via CD36-mediated endocytosis, associates with cytosolic FASN, inhibiting fatty acid synthase activity and leading to lipolysis, the degradation of triacylglycerols into glycerol and free fatty acids (FFA). CD5L-induced lipolysis occurs with progression of obesity: participates in obesity-associated inflammation following recruitment of inflammatory macrophages into adipose tissues, a cause of insulin resistance and obesity- related metabolic disease. Regulation of intracellular lipids mediated by CD5L has a direct effect on transcription regulation mediated by nuclear receptors ROR-gamma (RORC). Acts as a key regulator of metabolic switch in T-helper Th17 cells. Regulates the expression of pro-inflammatory genes in Th17 cells by altering the lipid content and limiting synthesis of cholesterol ligand of RORC, the master transcription factor of Th17-cell differentiation. CD5L is mainly present in non-pathogenic Th17 cells, where it decreases the content of polyunsaturated fatty acyls (PUFA), affecting two metabolic proteins MSMO1 and CYP51A1, which synthesize ligands of RORC, limiting RORC activity and expression of pro-inflammatory genes. Participates in obesity- associated autoimmunity via its association with IgM, interfering with the binding of IgM to Fcalpha/mu receptor and enhancing the development of long-lived plasma cells that produce high-affinity IgG autoantibodies. Also acts as an inhibitor of apoptosis in macrophages: promotes macrophage survival from the apoptotic effects of oxidized lipids in case of atherosclerosis (PubMed:24295828). Involved in early response to microbial infection against various pathogens by acting as a pattern recognition receptor and by promoting autophagy (PubMed:16030018, PubMed:24223991, PubMed:24583716, PubMed:25713983). [The UniProt Consortium]
Schlagworte: Anti-CD5L, Anti-CT-2, Anti-hAIM, Anti-API6, Anti-SP-alpha, Anti-CD5 antigen-like, Anti-IgM-associated peptide, Anti-Apoptosis inhibitor expressed by macrophages, Anti-IgM Monoclonal Antibody (Clone:CH2)
Hersteller: Abeomics
Hersteller-Nr: 30-1204

Eigenschaften

Anwendung: WB, FC, ICC, ELISA
Antikörper-Typ: Monoclonal
Klon: CH2
Konjugat: No
Wirt: Mouse
Spezies-Reaktivität: human
Immunogen: Purified human IgM.
Format: Purified

Datenbank Information

UniProt ID : O43866 | Passende Produkte
Gene ID GeneID 922 | Passende Produkte

Handhabung & Sicherheit

Lagerung: +4°C
Versand: +4°C (International: +4°C)
Achtung
Nur für Forschungszwecke und Laboruntersuchungen: Nicht für die Anwendung im oder am Menschen!
Hier kriegen Sie ein Zertifikat
oder , um Analysenzertifikate anzufordern.
Bewertungen lesen, schreiben und diskutieren... mehr
Kundenbewertungen für "Anti-IgM Monoclonal Antibody (Clone:CH2)"
Bewertung schreiben
oder , um eine Produktbewertung abzugeben.
Zuletzt angesehen